Kerendia▼ (finerenone) and the Kidneys

The promotional videos are intended for UK Healthcare Professionals (HCPs), and were organised and funded by Bayer PLC. Prescribing Information for Kerendia® (finerenone) and Adverse Event Reporting can be found here.

Part One | Diagnosing and understanding the risks of CKD

This video provides an overview of the importance of accurately diagnosing chronic kidney disease (CKD) in type 2 diabetes (T2D).

Part Two | Optimising managment of CKD in T2D

This video explores pharmacological treatment options for managing CKD associated with T2D.

Part Three | What is Kerendia and why should we prescribe it?

This video covers the clinical evidence behind use of Kerendia, emphasising why it should be considered as a treatment option for CKD in T2D.

Part Four | What is the profile of a potential Kerendia patient?

This video explores the types of patients who may be suitable for treatment with Kerendia.

Part Five | Prescribing Kerendia: initiation, continuation and hyperkalaemia managment

This video covers the factors to consider when prescribing Kerendia.

RP-KER-GB-1116 | March 2025

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.

Register Today

Keep up to date with the CVRMUK

The CVRMUK releases monthly newsletters to keep members updated on our ongoing activities. Sign up to keep in touch or follow us on social media.